 This is a single-center, randomized, single-blind, placebo-controlled, ascending single oral dose study designed to evaluate the safety, tolerability, and pharmacokinetic PK profiles of SEP-363856 and its metabolite SEP-363854 in male and female subjects with schizophrenia. 